

October 2025 Updates

Completed Rapid Reviews



- Selpercatinib (Retsevmo®) for advanced RET fusion-positive non-small cell lung cancer. HTA ID: 25035
- Inavolisib (Itovebi®). HTA ID: 25056
- Teprotumumab (Tepezza®) HTA ID: 25057
- Metreleptin (Myalepta®). HTA ID: 25058
- Vorasidenib (Voranigo®). HTA ID: 25059
- Semaglutide (Ozempic®) 2mg. HTA ID: 25060

Stay Informed



Keep updated with NCPE's initiatives at www.ncpe.ie